Leuprorelin acetate - Transgender Health - Children and Young People

With the publication of the final Cass Report and new NHSE commissioning policies, the APC has agreed an AMBER status for puberty supressing hormones in children and young people under the following circumstances:
i.    ONLY for current NHS and private patients at least until next reviewed by the service lead clinician.  Always ensure that appropriate shared care protocols are in place before continuing prescribing.  Private patients should be advised of the new NHS policy and recommendation made to return to the private provider for consideration of stopping.
ii.    DO NOT initiate in any new patients